12:00 AM
Sep 28, 2015
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Helsinn, Chugai sales and marketing update

Chugai launched Akynzeo netupitant/palonosetron in the U.K. to prevent chemotherapy-induced nausea and vomiting (CINV). The cost of the...

Read the full 90 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >